demonstrated that HSC infusion after myeloablative RT resulted in homing of tumor specific lymphocytes to the tumor (KR158) via CCL3 secretion and tumor control with improved survival (doubling of median survival compared to control) (79). This evidence concerns the gene CCL3 and neoplasm.